Marc Funk

Marc Funk is a Swiss life-sciences executive with more than two decades of experience in the pharmaceutical, biotechnology, and contract development and manufacturing organization (CDMO) sectors. He has held senior leadership positions at Lonza and Recipharm, and has served on the boards of several biotechnology companies.

Education

• Master of Law (LLM) – University of Geneva, Switzerland
• Master of Law and Diplomacy – The Fletcher School at Tufts University, USA
• He was also admitted to the Geneva Bar.
• Earlier in his career, he obtained certification as a gemologist from the Gemological Institute of America.

Career

GeneProt – 2000–2004

Marc Funk was a co-founder, Co-CEO and General Counsel of GeneProt, a biotechnology research company focused on proteomics. The company was subsequently transferred to Novartis.

Merck Serono – 2004–2008

He served as Associate General Counsel, working on global commercial contracts and legal matters involving the company's international operations.

Lonza – 2008–2020

Funk joined Lonza in 2008 as Chief Legal and Compliance Officer and later became Group General Counsel and Board Secretary. In 2014, he became Chief Operating Officer and President of Lonza Pharma & Biotech.

In March 2019, he was appointed CEO of Lonza Group, succeeding Richard Ridinger.

During his leadership of Lonza Pharma & Biotech, he was credited with transforming and expanding the business, including consolidating global operations and strengthening quality and operational standards.

Recipharm – 2021–2023

Marc Funk became CEO of Recipharm in March 2021. Under his leadership, the company expanded its capabilities in advanced biologics and acquired businesses including ArrantaBio, Vibalogics and GenIbet, while also establishing NewBiologix.

In January 2024, he transitioned from CEO to the Recipharm Board of Directors, where he continued supporting the company's strategic development.

Current / Recent Roles

• Board Member – Recipharm
• CEO & Board Member – MARBIO, a Moroccan vaccine-manufacturing joint venture
• Board Member – Chime Biologics
• Previously CEO – Recipharm
• Previously CEO – Lonza Group

Recipharm's current leadership page lists Marc Funk as a Board Member.

Major Areas of Expertise

• Pharmaceutical manufacturing
• Biopharmaceuticals
• CDMO strategy and operations
• Biologics manufacturing
• Cell and gene therapy
• Vaccine manufacturing
• Business transformation
• International healthcare strategy
• Corporate governance